Journal
JOURNAL OF THE NEUROLOGICAL SCIENCES
Volume 208, Issue 1-2, Pages 57-65Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/S0022-510X(02)00425-2
Keywords
multiple sclerosis; MRI; atrophy; brain parenchymal fraction; disability evaluation; T2 lesions; T1 black holes
Categories
Funding
- NINDS NIH HHS [1 K23 NS42379-01] Funding Source: Medline
Ask authors/readers for more resources
Brain atrophy is a proposed MRI marker of irreversible pathologic damage in multiple sclerosis (MS). The brain parenchymal fraction (BPF) is the ratio of brain parenchymal volume to the total Volume within the surface contour. We developed a semiautomated measure of BPF using commercially available edge-finding and thresholding software (30-min analysis time per patient). We measured BPF in 78 patients with MS and 17 healthy controls. BPF was lower in a cohort of patients with MS (n=50) (0.843 +/- 0.042, range 0.743-0.906) age-matched to controls (0.877 +/- 0.020, range 0.835-0.901) (p<0.001). BPF correlated inversely with third ventricular width (r = -0.785, p<0.001), and total T1 hypointense lesion volume (r = -0.347, p = 0.011), but not with total T2 hyperintense lesion volume (r = -0.213, p = 0.13). BPF correlated negatively with expanded disability status scale (EDSS) score (r = -0.391, p = 0.0006) and disease duration (r = -0.281,p = 0.01). Stepwise regression compared the relative abilities of MRI variables to predict clinical data. By regression of age, BPF, third ventricular width, T2 lesions, and T1 lesions, BPF was the best predictor of disability score (R(2) = 0.204, p<0.001). Third ventricular width was the best predictor of disease duration (R(2) = 0.316, p<0.001). None of the MRI variables differed between relapsing-remitting (RR) (n = 60) and secondary progressive (SP) (n = 18) disease course (p>0.05). The intrarater, interrater, and scan-rescan BPF variability (COV) was 0.31%, 0.34%, and 0.41% and the accuracy against a phantom was 99.1%. We conclude that whole-brain atrophy in MS can be reliably and readily quantified by a semautomated approach. Longitudinal studies are warranted to determine if this method provides a sensitive biologic marker of the MS disease process. (C) 2002 Elsevier Science B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available